Effect of the time to antivenom administration on recovery from snakebite envenoming-related coagulopathy in French Guiana.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
22
12
2022
accepted:
14
03
2023
revised:
04
05
2023
medline:
8
5
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Snakebite (SB) envenoming is an acute emergency requiring an early care delivery. We aimed to search for the time to reach healthcare facilities in various regions of French Guiana (FG) and to assess the impact of time to antivenom (AV) on the correction of coagulation parameters in these patients. This is a prospective observational study conducted in Cayenne General Hospital between January 1st, 2016, and July 31st, 2022. We included all patients hospitalized for SB envenoming less than 48h after the bite, and receiving antivenom (AV). We assessed the time lapse between SB and medical attention and the time needed to return of the coagulation parameters to normal. Overall, 119 patients were investigated, and 48.7% were from remote areas. The median time from SB to AV therapy was 09:15 h (05:32-17:47). The time was longer in patients from remote rural locations. AV was dispensed within the first six hours after the SB in 45 cases (37.8%). Time from SB to reaching normal plasma fibrinogen concentration was 23:27 h (20:00-27:10) in patients receiving AV≤6h vs. 31:23 h (24:00-45:05) in those receiving AV>6h (p<0.001). Whereas, the time from AV administration to reach normal fibrinogen dosage was similar in the two groups. Patients from rural settings in FG suffer from a delay in AV administration after SB envenoming leading to an extended time in which patients are coagulopathic. Once AV is administered, clotting parameters recover at a similar rate. Supplying remote healthcare facilities with AV and with medical teams trained on its use should be planned.
Sections du résumé
BACKGROUND
Snakebite (SB) envenoming is an acute emergency requiring an early care delivery. We aimed to search for the time to reach healthcare facilities in various regions of French Guiana (FG) and to assess the impact of time to antivenom (AV) on the correction of coagulation parameters in these patients.
METHODOLOGY
This is a prospective observational study conducted in Cayenne General Hospital between January 1st, 2016, and July 31st, 2022. We included all patients hospitalized for SB envenoming less than 48h after the bite, and receiving antivenom (AV). We assessed the time lapse between SB and medical attention and the time needed to return of the coagulation parameters to normal.
PRINCIPAL FINDINGS
Overall, 119 patients were investigated, and 48.7% were from remote areas. The median time from SB to AV therapy was 09:15 h (05:32-17:47). The time was longer in patients from remote rural locations. AV was dispensed within the first six hours after the SB in 45 cases (37.8%). Time from SB to reaching normal plasma fibrinogen concentration was 23:27 h (20:00-27:10) in patients receiving AV≤6h vs. 31:23 h (24:00-45:05) in those receiving AV>6h (p<0.001). Whereas, the time from AV administration to reach normal fibrinogen dosage was similar in the two groups.
CONCLUSIONS
Patients from rural settings in FG suffer from a delay in AV administration after SB envenoming leading to an extended time in which patients are coagulopathic. Once AV is administered, clotting parameters recover at a similar rate. Supplying remote healthcare facilities with AV and with medical teams trained on its use should be planned.
Identifiants
pubmed: 37093856
doi: 10.1371/journal.pntd.0011242
pii: PNTD-D-22-01606
pmc: PMC10159357
doi:
Substances chimiques
Antivenins
0
Fibrinogen
9001-32-5
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011242Informations de copyright
Copyright: © 2023 Houcke et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2018 Aug 17;13(8):e0202361
pubmed: 30118505
Rev Inst Med Trop Sao Paulo. 2002 May-Jun;44(3):133-8
pubmed: 12163905
PLoS Negl Trop Dis. 2017 Nov 27;11(11):e0006068
pubmed: 29176824
Toxicon. 2013 Dec 15;76:103-9
pubmed: 24070638
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
PLoS Negl Trop Dis. 2021 Mar 4;15(3):e0009245
pubmed: 33661895
Front Med (Lausanne). 2022 Mar 07;9:852651
pubmed: 35321467
Rev Panam Salud Publica. 2018 May 04;42:e52
pubmed: 31093080
Toxicon. 2012 Feb;59(2):344-55
pubmed: 22146491
Toxicon. 2018 May;146:91-94
pubmed: 29621524
Toxicon X. 2022 Oct 22;16:100139
pubmed: 36325535
Rev Soc Bras Med Trop. 2022 Jul 25;55:e05582021
pubmed: 35894402
Toxicon. 2018 Jun 15;148:50-55
pubmed: 29654867
Clin Toxicol (Phila). 2020 Apr;58(4):266-274
pubmed: 31264481
Toxins (Basel). 2020 Oct 19;12(10):
pubmed: 33086750
Br J Clin Pharmacol. 2016 Mar;81(3):446-52
pubmed: 26256124
Clin Toxicol (Phila). 2021 Mar;59(3):193-199
pubmed: 32609546
Toxicon. 2018 Sep 1;151:15-23
pubmed: 29908262
Med Trop (Mars). 2002;62(2):177-84
pubmed: 12192717
Am Fam Physician. 2018 Sep 15;98(6):354-361
pubmed: 30215915
PLoS One. 2015 Jul 13;10(7):e0132237
pubmed: 26168155
Trans R Soc Trop Med Hyg. 1998 Sep-Oct;92(5):542-5
pubmed: 9861375
Trans R Soc Trop Med Hyg. 1992 Sep-Oct;86(5):562-4
pubmed: 1475835
Lancet Glob Health. 2019 Jul;7(7):e837-e838
pubmed: 31129124